Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y. Nakano S, et al. Among authors: ishiguro a. Int J Clin Oncol. 2020 Oct;25(10):1800-1806. doi: 10.1007/s10147-020-01720-y. Epub 2020 Jul 14. Int J Clin Oncol. 2020. PMID: 32666389 Free PMC article.
A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01).
Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y. Nakamura M, et al. Among authors: ishiguro a. Oncologist. 2017 May;22(5):592-600. doi: 10.1634/theoncologist.2016-0308. Epub 2017 Mar 24. Oncologist. 2017. PMID: 28341762 Free PMC article. Clinical Trial.
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Kawamoto Y, et al. Among authors: ishiguro a. BMC Cancer. 2017 Dec 8;17(1):837. doi: 10.1186/s12885-017-3850-z. BMC Cancer. 2017. PMID: 29221445 Free PMC article. Clinical Trial.
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J. Okano N, et al. Among authors: ishiguro a. Int J Clin Oncol. 2020 Oct;25(10):1835-1843. doi: 10.1007/s10147-020-01721-x. Epub 2020 Jun 13. Int J Clin Oncol. 2020. PMID: 32535711 Clinical Trial.
A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: ishiguro a. Oncologist. 2021 Oct;26(10):e1675-e1682. doi: 10.1002/onco.13838. Epub 2021 Jun 21. Oncologist. 2021. PMID: 34050586 Free PMC article. Clinical Trial.
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Kakeji Y, et al. Among authors: ishiguro a. Gastric Cancer. 2022 Jan;25(1):188-196. doi: 10.1007/s10120-021-01224-2. Epub 2021 Aug 5. Gastric Cancer. 2022. PMID: 34351555 Clinical Trial.
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y. Ito K, et al. Among authors: ishiguro a. Support Care Cancer. 2022 Jun;30(6):5351-5359. doi: 10.1007/s00520-022-06936-4. Epub 2022 Mar 15. Support Care Cancer. 2022. PMID: 35292848 Free PMC article.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y. Nakano S, et al. Among authors: ishiguro a. BMJ Open. 2022 May 9;12(5):e048833. doi: 10.1136/bmjopen-2021-048833. BMJ Open. 2022. PMID: 35534074 Free PMC article.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: ishiguro a. Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086. Oncologist. 2022. PMID: 35579511 Free PMC article. Clinical Trial.
470 results